financetom
Business
financetom
/
Business
/
Adobe Customers Wait for AI to Take Shape in Products, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Adobe Customers Wait for AI to Take Shape in Products, Morgan Stanley Says
Jun 10, 2024 10:24 AM

01:07 PM EDT, 06/10/2024 (MT Newswires) -- Adobe's (ADBE) performance during fiscal Q2 still faced soft spending, but the second half is expected to offset that as spending budgets get replenished and integration of artificial intelligence takes shape, Morgan Stanley said Monday.

The company is scheduled to release fiscal Q2 results June 13. After seeing soft spending at enterprise software companies like Salesforce (CRM), Workday (WDAY) and others, investors were concerned if Adobe faced the same sentiment during Q2. However, its partners told the brokerage the AI integration could invigorate interest.

Partners didn't see the usual increase in the back half of the quarter as enterprises are in a wait-and-see approach as it relates to artificial intelligence, making the Morgan Stanley "a bit more nervous" around the growth of Digital Experience business.

"While Q2 remains a difficult set-up with pricing headwinds in Digital Media and enterprise software malaise in Digital Experience, given the weak investor sentiment, ramping product cycles and easing comps in H2, it may prove a clearing event," the firm said.

Morgan Stanley had an overweight rating and $660 price target on Adobe.

Price: 459.24, Change: -6.19, Percent Change: -1.33

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cash-strapped US farmers switch to generic crop chemicals, in blow to big manufacturers
Cash-strapped US farmers switch to generic crop chemicals, in blow to big manufacturers
Nov 15, 2024
(Reuters) - U.S. farmers struggling with slumping incomes and depressed grain prices have been switching to cheaper generic pesticides and fungicides as they plan for spring planting next year, which market analysts said could hit the bottom lines of agrichemical companies like Bayer. Signs of these financial impacts are already emerging. Bayer shares fell sharply to a 20-year low on...
Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
Nov 15, 2024
Nov 14 (Reuters) - Merck ( MRK ) has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday. The deal allows Merck ( MRK ) to take over development of LaNova's LM-299, a drug candidate targeting a protein called PD-1, which...
AtkinsRealis Q3 Adjusted Profit, Revenue Increase
AtkinsRealis Q3 Adjusted Profit, Revenue Increase
Nov 15, 2024
07:03 AM EST, 11/14/2024 (MT Newswires) -- AtkinsRealis ( SNCAF ) on Thursday said third-quarter adjusted profit and revenue rose. The engineering services and nuclear company said adjusted profit attributable to shareholders from professional services and project management (PS&PM) increased 64% to $110.1 million, or $0.63 per diluted share, from $67.3 million, or $0.38 per diluted share, last year. Services...
GSK Reports Positive Results from Phase 3 Trial for Blenrep in Multiple Myeloma Treatment
GSK Reports Positive Results from Phase 3 Trial for Blenrep in Multiple Myeloma Treatment
Nov 15, 2024
07:05 AM EST, 11/14/2024 (MT Newswires) -- GSK (GSK) said Thursday that the interim analysis of the DREAMM-7 head-to-head phase three trial evaluating Blenrep, or belantamab mafodotin, in combination with bortezomib plus dexamethasone, or BorDex, as a second-line or later treatment for relapsed or refractory multiple myeloma showed positive headline results. The trial met its key secondary endpoint of overall...
Copyright 2023-2026 - www.financetom.com All Rights Reserved